PUBLIC COMPANY
saveShanghai Henlius Biotech Inc
updated 4mo ago
community read0 votes
🐶 often sniffed alongside
top 8- tagOncology9 co-mentions · 3 sources
- tagApproval6 co-mentions · 3 sources
- tagBreast Cancer5 co-mentions · 1 sources
- drugBILPREVDA4 co-mentions · 2 sources
- tagNSCLC3 co-mentions · 2 sources
- tagPulmonology2 co-mentions · 2 sources
- drugpertuzumab biosimilar2 co-mentions · 1 sources
- drugdenosumab2 co-mentions · 2 sources
pipeline
8
marketed
1
phase 3
3
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(8)
pipeline depth8 products
3Phase 31Marketed3Unknown1pre_registration
Marketed
BILPREVDA
Phase 3HLX-43
Squamous Non-Small Cell Lung Cancer
Phase 3dulpatatug
Adenocarcinoma Of The Gastroesophageal Junction
Phase 3serplulimab
Small-Cell Lung Cancer
Programmed cell death protein 1
drugHLX-35
drugHLX-3901
drugPOHERDY
pre_registrationbevacizumab biosimilar
Cervical Cancer
Vascular endothelial growth factor A, long form
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- AstraZeneca scores in lung cancer; Sandoz inks a China dealA combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.biopharma_dive · 1mo ago
- Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsThe initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.biospace · 1mo ago
- STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and moreAstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacksstat · 1mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that